- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-TNFL8/ TNFSF8/ CD153 monoclonal antibody
Anti-TNFL8/ TNFSF8/ CD153 antibody for FACS & in-vivo assay
Go to TNFSF8/TNFSF8 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-MP1859-Ab-1/ GM-Tg-hg-MP1859-Ab-2 | Anti-Human TNFSF8 monoclonal antibody | Human |
| GM-Tg-rg-MP1859-Ab-1/ GM-Tg-rg-MP1859-Ab-2 | Anti-Rat TNFSF8 monoclonal antibody | Rat |
| GM-Tg-mg-MP1859-Ab-1/ GM-Tg-mg-MP1859-Ab-2 | Anti-Mouse TNFSF8 monoclonal antibody | Mouse |
| GM-Tg-cynog-MP1859-Ab-1/ GM-Tg-cynog-MP1859-Ab-2 | Anti-Cynomolgus/ Rhesus macaque TNFSF8 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-MP1859-Ab-1/ GM-Tg-felg-MP1859-Ab-2 | Anti-Feline TNFSF8 monoclonal antibody | Feline |
| GM-Tg-cang-MP1859-Ab-1/ GM-Tg-cang-MP1859-Ab-2 | Anti-Canine TNFSF8 monoclonal antibody | Canine |
| GM-Tg-bovg-MP1859-Ab-1/ GM-Tg-bovg-MP1859-Ab-2 | Anti-Bovine TNFSF8 monoclonal antibody | Bovine |
| GM-Tg-equg-MP1859-Ab-1/ GM-Tg-equg-MP1859-Ab-2 | Anti-Equine TNFSF8 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-MP1859-Ab-1/ GM-Tg-hg-MP1859-Ab-2; GM-Tg-rg-MP1859-Ab-1/ GM-Tg-rg-MP1859-Ab-2; GM-Tg-mg-MP1859-Ab-1/ GM-Tg-mg-MP1859-Ab-2; GM-Tg-cynog-MP1859-Ab-1/ GM-Tg-cynog-MP1859-Ab-2; GM-Tg-felg-MP1859-Ab-1/ GM-Tg-felg-MP1859-Ab-2; GM-Tg-cang-MP1859-Ab-1/ GM-Tg-cang-MP1859-Ab-2; GM-Tg-bovg-MP1859-Ab-1/ GM-Tg-bovg-MP1859-Ab-2; GM-Tg-equg-MP1859-Ab-1/ GM-Tg-equg-MP1859-Ab-2 |
| Products Name | Anti-TNFSF8 monoclonal antibody |
| Format | mab |
| Target Name | TNFSF8 |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody, Cytokine antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-TNFSF8 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | Products Developing | Multi-species TNFL8/ TNFSF8/ CD153 VLP (virus-like particle) (Products Developing) |
| Cytokine | GM-Tg-g-MP1859-Ag-1 | tumor necrosis factor (ligand) superfamily, member 8 (Tnfsf8) protein |
| ORF Viral Vector | vGMLP004531 | human TNFSF8 Lentivirus particle |
| ORF Viral Vector | pGMLP004531 | human TNFSF8 Lentivirus plasmid |
| ORF Viral Vector | pGMLPm000510 | mouse Tnfsf8 Lentivirus plasmid |
| ORF Viral Vector | vGMLPm000510 | mouse Tnfsf8 Lentivirus particle |
Target information
| Target ID | GM-MP1859 |
| Target Name | TNFSF8 |
| Gene ID | 944,21949,683163,702944,612608,101099756,574056,100051061 |
| Gene Symbol and Synonyms | CD153,CD30L,CD30LG,TNFRSF8,TNFSF8,TNLG3A |
| Uniprot Accession | P32971 |
| Uniprot Entry Name | TNFL8_HUMAN |
| Protein Sub-location | Transmembrane Protein |
| Category | Cytokine Target |
| Disease | Lung Cancer |
| Gene Ensembl | ENSG00000106952 |
| Target Classification | N/A |
The target: TNFSF8, gene name: TNFSF8, also named as CD153, CD30L, CD30LG, TNLG3A. The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This cytokine is a ligand for TNFRSF8/CD30, which is a cell surface antigen and a marker for Hodgkin lymphoma and related hematologic malignancies. The engagement of this cytokine expressed on B cell surface plays an inhibitory role in modulating Ig class switch. This cytokine was shown to enhance cell proliferation of some lymphoma cell lines, while to induce cell death and reduce cell proliferation of other lymphoma cell lines. The pleiotropic biologic activities of this cytokine on different CD30+ lymphoma cell lines may play a pathophysiologic role in Hodgkin's and some non-Hodgkin's lymphomas. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2011].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
